Patients With Celiac Disease and B-Cell Lymphoma Have a Better Prognosis Than Those With T-Cell Lymphoma

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 12, 2010, Pages 1042-1047

  Halfdanarson, Thorvardur R ^a   Rubio Tapia, Alberto ^b   Ristow, Kay M ^a   Habermann, Thomas M ^a   Murray, Joseph A ^b   Inwards, David J ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cancer; Enteropathy; GI Disease; Gluten

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELIAC DISEASE; CHILD; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; ENTEROPATHY TYPE T CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONENTEROPATHY TYPE T CELL LYMPHOMA; PROGNOSIS; SCHOOL CHILD; SURVIVAL RATE; T CELL LYMPHOMA; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELIAC DISEASE; CHILD; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649693366     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.09.007     Document Type: Article

References (47)

1. Green P.H., Cellier C. Celiac disease. N Engl J Med 2007, 357:1731-1743.
2. Fasano A., Berti I., Gerarduzzi T., et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003, 163:286-292.
3. Maki M., Mustalahti K., Kokkonen J., et al. Prevalence of celiac disease among children in Finland. N Engl J Med 2003, 348:2517-2524.
4. Rubio-Tapia A., Kyle R.A., Kaplan E.L., et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology 2009, 137:88-93.
5. Rostom A., Murray J.A., Kagnoff M.F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006, 131:1981-2002.
6. Halfdanarson T.R., Litzow M.R., Murray J.A. Hematologic manifestations of celiac disease. Blood 2007, 109:412-421.
7. Catassi C., Fabiani E., Corrao G., et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002, 287:1413-1419.
8. Gao Y., Kristinsson S.Y., Goldin L.R., et al. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology 2009, 136:91-98.
9. Mearin M.L., Catassi C., Brousse N., et al. European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol 2006, 18:187-194.
10. Smedby K.E., Akerman M., Hildebrand H., et al. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathy-type T cell lymphoma. Gut 2005, 54:54-59.
11. Catassi C., Bearzi I., Holmes G.K. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005, 128:S79-S86.
12. Isaacson P., Wright D.H. Intestinal lymphoma associated with malabsorption. Lancet 1978, 1:67-70.
13. Leonard J.N., Tucker W.F., Fry J.S., et al. Increased incidence of malignancy in dermatitis herpetiformis. Br Med J (Clin Res Ed) 1983, 286:16-18.
14. Al-Toma A., Verbeek W.H., Hadithi M., et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007, 56:1373-1378.
15. Verbeek W.H., Van De Water J.M., Al-Toma A., et al. Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol 2008, 43:1-7.
16. Gale J., Simmonds P.D., Mead G.M., et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000, 18:795-803.
17. Holmes G.K., Prior P., Lane M.R., et al. Malignancy in coeliac disease--effect of a gluten free diet. Gut 1989, 30:333-338.
18. Collin P., Reunala T., Pukkala E., et al. Coeliac disease-associated disorders and survival. Gut 1994, 35:1215-1218.
19. Rubio-Tapia A., Rahim M.W., See J.A., et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010, 105:1412-1420.
20. Kaukinen K., Peraaho M., Lindfors K., et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007, 25:1237-1245.
21. Mention J.J., Ben Ahmed M., Begue B., et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003, 125:730-745.
22. Cellier C., Patey N., Mauvieux L., et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998, 114:471-481.
23. Cellier C., Delabesse E., Helmer C., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Coeliac Disease Study Group [French]. Lancet 2000, 356:203-208.
24. Daum S., Hummel M., Weiss D., et al. Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma. Digestion 2000, 62:60-65.
25. Rubio-Tapia A., Kelly D.G., Lahr B.D., et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009, 136:99-107. quiz 352-353.
26. Malamut G., Afchain P., Verkarre V., et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136:81-90.
27. Daum S., Ipczynski R., Schumann M., et al. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009, 21:66-70.
28. Rubio-Tapia A., Murray J.A. Classification and management of refractory coeliac disease. Gut 2010, 59:547-557.
29. Cellier C., Cerf-Bensussan N. Treatment of clonal refractory celiac disease or cryptic intraepithelial lymphoma: a long road from bench to bedside. Clin Gastroenterol Hepatol 2006, 4:1320-1321.
30. Deleeuw R.J., Zettl A., Klinker E., et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007, 132:1902-1911.
31. Verkarre V., Romana S.P., Cellier C., et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003, 125:40-46.
32. Zettl A., Ott G., Makulik A., et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002, 161:1635-1645.
33. Al-Toma A., Goerres M.S., Meijer J.W., et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006, 4:315-319.
34. Wolters V.M., Verbeek W.H., Zhernakova A., et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin Gastroenterol Hepatol 2007, 5:1399-1405. e1-2.
35. Lennard A. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T-cell lymphoma. Br J Haematol 2007, 137:170. author reply 171.
36. Al-Toma A., Verbeek W.H., Visser O.J., et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007, 39:634-641.
37. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
38. Armitage J.O. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005, 55:368-376.
39. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
40. Smedby K.E., Hjalgrim H., Askling J., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006, 98:51-60.
41. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
42. Egan L.J., Walsh S.V., Stevens F.M., et al. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995, 21:123-129.
43. Bishton M.J., Haynes A.P. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 2007, 136:111-113.
44. Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplant. Blood 2010, 115:3664-3670.
45. Collin P., Pukkala E., Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996, 38:528-530.
46. Sigurgeirsson B., Agnarsson B.A., Lindelof B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994, 308:13-15.
47. Murray J.A., Van Dyke C., Plevak M.F., et al. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003, 1:19-27.